Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium

July 1, 2024

https://www.globenewswire.com/news-release/2024/07/01/2906759/0/en/Artelo-Biosciences-Presents-Preclinical-Data-on-ART26-12-in-Breast-Cancer-Induced-Bone-Pain-at-the-34th-Annual-International-Cannabinoid-Research-Society-Symposium.html

SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium being held June 30 to July 5, 2024 in Salamanca, Spain.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.